Rotavirus vaccine and health care utilization for diarrhea in U.S. children

Jennifer E Cortes1, Aaron T Curns, Jacqueline E Tate

  • 1Epidemic Intelligence Service, Office of Workforce and Career Development, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

Insights

Routine rotavirus vaccination (RV5) significantly reduced diarrhea-related healthcare use and costs in U.S. children. The vaccine led to substantial decreases in hospitalizations and emergency visits, saving millions in treatment costs.

Area of Science:

  • Public Health
  • Vaccinology
  • Pediatric Gastroenterology

Background:

  • Pentavalent rotavirus vaccine (RV5) was introduced for routine U.S. infant vaccination in 2006.
  • Monitoring vaccine impact on healthcare utilization is crucial for public health policy.

Purpose of the Study:

  • To assess the impact of rotavirus vaccine (RV5) on diarrhea-associated healthcare utilization and costs in U.S. children.
  • To estimate indirect benefits of RV5 vaccination in unvaccinated children.

Main Methods:

  • Utilized MarketScan databases to analyze RV5 coverage and diarrhea-related healthcare use from 2001-2009 in children under 5.
  • Compared healthcare use rates in vaccinated and unvaccinated children during rotavirus season.
  • Extrapolated national reductions in hospitalizations and associated costs.

Main Results:

  • By late 2008, RV5 coverage reached 73% in infants and 64% in 1-year-olds.
  • Diarrhea hospitalizations decreased by 33% in 2007-2008 and 25% in 2008-2009 post-vaccine introduction.
  • Rotavirus-specific hospitalizations saw reductions of 75% and 60% in the respective periods.
  • Significant reductions were observed in emergency department and outpatient visits for diarrhea.
  • Nationally, an estimated 64,855 hospitalizations were averted, saving approximately $278 million between 2007-2009.

Conclusions:

  • The introduction of rotavirus vaccine has led to substantial decreases in diarrhea-associated healthcare utilization and medical expenditures among U.S. children.
  • RV5 vaccination demonstrates significant public health benefits through reduced disease burden and healthcare costs.
Abstract

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Cholera01:25

Cholera

Cholera is an acute gastrointestinal disease caused by the Gram-negative bacterium Vibrio cholerae. It is transmitted primarily via the fecal-oral route through the ingestion of contaminated water or food.Vibrio cholerae is a motile, Gram-negative bacterium of the family Vibrionaceae, primarily associated with waterborne outbreaks in areas with inadequate sanitation. Although over 200 serogroups of V. cholerae exist, only O1 and O139 are responsible for epidemic cholera. The O1 serogroup,...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...